

ARTICLE OPEN



PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia

Gábor Bedics^{1,14}, Bálint Egyed^{1,2,14}, Lili Kotmayer¹, Anne Benard-Slagter³, Karel de Groot³, Anna Bekő¹, Lajos László Hegyi¹, Bence Bártai¹, Szilvia Krizsán¹, Gergely Kriván⁴, Dániel J. Erdélyi², Judit Müller², Irén Haltrich², Béla Kajtár⁵, László Pajor⁵, Ágnes Vojcek⁶, Gábor Ottóffy⁶, Anikó Ujfalusi⁷, István Szegedi⁸, Lilla Györgyi Tiszlavicz⁹, Katalin Bartyik⁹, Krisztina Csanádi¹⁰, György Péter¹⁰, Réka Simon¹¹, Péter Hauser¹¹, Ágnes Kelemen¹¹, Endre Sebestyén¹, Zsuzsanna Jakab¹², András Matolcsy^{1,13}, Csongor Kiss⁸, Gábor Kovács², Suvi Savola³, Csaba Bödör¹ and Donát Alpar¹✉

© The Author(s) 2023

BACKGROUND: Recurrent genetic lesions provide basis for risk assessment in pediatric acute lymphoblastic leukemia (ALL). However, current prognostic classifiers rely on a limited number of predefined sets of alterations.

METHODS: Disease-relevant copy number aberrations (CNAs) were screened genome-wide in 260 children with B-cell precursor ALL. Results were integrated with cytogenetic data to improve risk assessment.

RESULTS: CNAs were detected in 93.8% ($n = 244$) of the patients. First, cytogenetic profiles were combined with *IKZF1* status (*IKZF1*^{normal}, *IKZF1*^{del} and *IKZF1*^{plus}) and three prognostic subgroups were distinguished with significantly different 5-year event-free survival (EFS) rates, IKAROS-low ($n = 215$): 86.3%, IKAROS-medium ($n = 27$): 57.4% and IKAROS-high ($n = 18$): 37.5%. Second, contribution of genetic aberrations to the clinical outcome was assessed and an aberration-specific score was assigned to each prognostically relevant alteration. By aggregating the scores of aberrations emerging in individual patients, personalized cumulative values were calculated and used for defining four prognostic subgroups with distinct clinical outcomes. Two favorable subgroups included 60% of patients ($n = 157$) with a 5-year EFS of 96.3% (excellent risk, $n = 105$) and 87.2% (good risk, $n = 52$), respectively; while 40% of patients ($n = 103$) showed high ($n = 74$) or ultra-poor ($n = 29$) risk profile (5-year EFS: 67.4% and 39.0%, respectively).

CONCLUSIONS: PersonALL, our conceptually novel prognostic classifier considers all combinations of co-segregating genetic alterations, providing a highly personalized patient stratification.

British Journal of Cancer; <https://doi.org/10.1038/s41416-023-02309-8>

INTRODUCTION

Cancer is a leading cause of death among children in the Western countries, with leukemia being the most common malignant disorder in this age group [1]. Acute lymphoblastic leukemia (ALL) accounts for 80% of all pediatric leukemia cases and displays B-cell precursor phenotype (B-ALL) in approximately 85% of the patients [2]. Pediatric ALL develops in multiple steps, with the initiating genomic lesion emerging in utero, as demonstrated in major genetic subtypes, followed by the rise of secondary aberrations required for the clinical manifestation of the disease [3–5]. Copy number aberrations (CNAs) such as whole chromosome gains and losses as well as subchromosomal imbalances recurrently occur as

primary or secondary alterations, substantially contributing to the heterogeneous genomic landscape of ALL [6–9].

The vast majority of numerical chromosome aberrations emerge in the high-hyperdiploid subgroup which accounts for 25–30% of pediatric B-ALL patients, with the leukemic blasts in this subgroup bearing non-random gains of specific chromosomes conferring a modal chromosome number of 51–67 [10, 11]. Subchromosomal CNAs recurrently affect genes involved in cell cycle control, tumor suppression, lymphoid cell development and B-cell differentiation [6]. A wide range of methods is available for the screening of CNAs in pediatric ALL, including karyotyping, fluorescence in situ hybridization (FISH), DNA index measurement,

¹HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. ²Department of Pediatrics, Semmelweis University, Budapest, Hungary. ³MRC Holland, Amsterdam, The Netherlands. ⁴Central Hospital of Southern Pest - National Institute of Hematology and Infectious Diseases, Budapest, Hungary. ⁵Department of Pathology, University of Pécs Medical School, Pécs, Hungary. ⁶Department of Pediatrics, University of Pécs Medical School, Pécs, Hungary. ⁷Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. ⁸Division of Pediatric Hematology-Oncology, Institute of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. ⁹Department of Paediatrics and Paediatric Health Care Center, Faculty of Medicine, University of Szeged, Szeged, Hungary. ¹⁰Hemato-Oncology Unit, Heim Pál Children's Hospital, Budapest, Hungary. ¹¹Hemato-Oncology and Stem Cell Transplantation Unit, Velkey László Children's Health Center, Miskolc, Hungary. ¹²Hungarian Childhood Cancer Registry, Hungarian Pediatric Oncology Network, Budapest, Hungary. ¹³Department of Laboratory Medicine, Karolinska Institute, Solna, Sweden. ¹⁴These authors contributed equally: Gábor Bedics, Bálint Egyed. ✉email: alpar.donat@med.semmelweis-univ.hu

Received: 20 September 2022 Revised: 8 May 2023 Accepted: 5 June 2023

Published online: 21 June 2023

multiplex ligation-dependent probe amplification (MLPA), cytogenomics, optical genome mapping as well as various array- and next-generation sequencing (NGS) based approaches [5, 6, 12–14]. digitalMLPA is a recently developed technique which combines MLPA with NGS readout providing a high-throughput, scalable, highly rationalized but still comprehensive means to interrogate recurrently affected genomic loci with a short turn-around time as previously demonstrated by our group and others [15–17].

Several studies investigated the clinical significance of CNAs in pediatric ALL and identified a range of prognostic biomarkers based on modal chromosome number [18–21], specific trisomies [19, 20, 22, 23], double or triple trisomies [19–21, 24, 25], simultaneous presence and absence of various trisomies [26], loss or gain/amplification of key driver genes [27, 28], as well as specific alteration patterns of predefined gene sets [29]. These observations facilitated the widespread implementation of CNA screening in the diagnostics of pediatric ALL, with an aim to support patient stratification and potentially aid therapy selection. Integrative efforts have led to the establishment of complex classifiers enabling the assignment of patients to distinct prognostic subgroups based on cytogenetic and molecular genetic markers [16, 29–31]. Shortcomings of current genetic classifiers are the relatively low number and limited combinations of aberrations used as criteria for decision making. Assignment of individual patients is typically restricted to a couple of specific genomic patterns; for example, trisomy of chromosomes 17 and/or 18 without extra copies of chromosomes 5 and 20; isolated *IKZF1* deletion; isolated deletion of *ETV6*, *PAX5* or *BTG1*; co-occurrence of *IKZF1* deletion with deletion of *CDKN2A*, *CDKN2B*, *PAX5* or *PAR1* in the absence of *ERG* deletion; *ETV6* deletion with single deletion of *BTG1*, *CDKN2A/B* or *PAX5*, with all other uncategoryable patients being classified in the same non-specific, collective subgroup.

In this study, we performed a comprehensive screening for disease-relevant CNAs in a cohort of Hungarian patients diagnosed with pediatric B-ALL using digitalMLPA. The generated CNA profiles were combined with cytogenetic data for risk assessment. Besides integrating *IKZF1* status (*IKZF1*^{normal}, *IKZF1*^{del} and *IKZF1*^{plus}) with cytogenetic classes, thus creating a cytogenetics aware interpretation of *IKZF1* imbalance, we introduced a conceptually novel patient classification approach called PersonALL, which assigns patients to prognostic subgroups based on highly individualized cumulative scores reflecting the weighted impact of all relevant aberrations detected in a particular patient. This newly developed prognostic classifier which flexibly considers all possible combinations of screened and potentially co-segregating genetic alterations provides a more refined, hence more personalized risk assessment for children with B-ALL.

MATERIALS AND METHODS

Patient samples

In the frame of the Hungarian Pediatric Leukemia Molecular Profiling Program, diagnostic bone marrow samples from 260 patients (male:female ratio: 1.43:1) diagnosed with B-cell precursor ALL at age 1–17 years (median: 5 years) were investigated (Table S1). Diagnoses were made based on morphological, immunophenotypical and genotypical criteria in the Department of Pathology and Experimental Cancer Research, Semmelweis University, in the Department of Pathology, University of Pécs, or in the Department of Pathology, University of Debrecen between 2003 and 2019 [2, 32]. Specimens contained on average 79% (range: 29–99%) leukemic blasts as assessed by flow cytometry (Table S1). Baseline genetic characterization of patient samples included DNA index measurement by flow cytometry, karyotyping by GTG-banding, FISH for *BCR-ABL1* and *ETV6-RUNX1* fusions, *KMT2A* and *E2A* rearrangements, and trisomy of chromosomes 4 and 10 using Vysis probes (Abbott Diagnostics, Abbott Park, IL, USA), as well as quantitative PCR tests for *BCR-ABL1* and *ETV6-RUNX1* fusions, and conventional MLPA using the SALSA 202 and 335 probemixes (MRC-Holland, Amsterdam, the Netherlands). Risk

assessment and treatment selection were performed according to ALL IC-BFM protocols, such as the ALL IC-BFM 2002 (121 patients, 47%) and ALL IC-BFM 2009 (139 patients, 53%) (Table S1) [33]. Standard-risk (SR), medium-risk (MR) and high-risk (HR) groups were represented by 35%, 52% and 13% as well as by 16%, 65% and 19% of the patients in cohorts treated with ALL IC-BFM 2002 and ALL IC-BFM 2009, respectively. The estimated 5-year event-free survival (EFS) rates were similar in groups of patients treated with different versions of the ALL IC-BFM protocol (ALL IC-BFM 2002: 77.8%, ALL IC-BFM 2009: 81.6%, log-rank test: $p = 0.530$, Fig. S1); therefore, data from all 260 patients were combined. In the entire discovery cohort, 65 (25%), 153 (59%) and 42 (16%) patients were stratified in the SR, MR and HR groups, respectively. Ethical approval (45563-2/2019/EKU) from the Medical Research Council of Hungary and written informed consent from the patients and/or from the parents or guardians were obtained for the study, which was conducted in accordance with the Declaration of Helsinki.

digitalMLPA

digitalMLPA reactions were performed on 40 ng genomic DNA using the D007 ALL probemix (version D007-X2-0516 or D007-X5-0220), which was developed by the MRC-Holland and provided to collaborating laboratories for testing and validation. The probemix consisted of (i) target probes for regions recurrently altered by copy number aberrations in acute lymphoblastic leukemia; (ii) digital karyotyping probes covering all chromosome arms for detection of gross chromosomal aberrations and serving as reference probes for data normalization, and (iii) internal control probes for quality control and sample identification. List and position of probes included in the D007-X2-0516 and D007-X5-0220 versions of the D007 probemix are presented in Table S2.

digitalMLPA reactions were carried out according to the previously published protocol [15, 16]. Briefly, individual DNA samples were mixed with a unique barcode solution followed by sample denaturation and addition of digitalMLPA probes with digitalMLPA buffer to the reaction mix. Each probe comprised two oligonucleotides with a locus-specific 25–50 bp hybridizing sequence. Probe oligonucleotides binding to target region were designed to hybridize adjacently; hence, if perfectly bound, could be ligated into a complete probe using the ligase-65 enzyme. Ligated probes were amplified by universal primers compatible with Illumina sequencing platforms. Sample-specific PCR products from different reactions were pooled and sequenced on a MiSeq v3 standard flow cell (Illumina, San Diego, CA, USA) using 110 bp or 115 bp single-read chemistry.

Copy number status at each interrogated locus was determined from the NGS output in two consecutive steps using the Coffalyser digitalMLPA software v.004 (MRC Holland). First, read count for each probe was normalized by the read counts generated from reference probes hybridizing to copy number stable regions of the same genome. Second, the relative read count calculated for each probe was compared with the matching values of all reference samples. The final probe ratio value (dosage quotient) was around 1.0 if the analyzed region was unaffected by CNA, while an increased or decreased value indicated the presence and level of gain or loss, respectively. Leukemic cell purity as assessed by flow cytometry was also considered at the interpretation of the results. CNAs were reported as being subclonal if multiple consecutive probes had dosage quotients unambiguously falling outside the normal range but without reaching the expected level of monoallelic loss as calculated based on sample purity, and also compared with other altered regions within the same specimen. Detailed laboratory and bioinformatic protocols as well as validation methods have previously been published [15, 16].

Validation cohort—origin and analysis

The independent validation cohort comprised 606 patients included in the Acute Lymphoblastic Leukemia Pilot Phase 1 (phs000463) or the Expansion Phase 2 (phs000464) studies of the Therapeutically Applicable Research to Generate Effective Treatments—TARGET initiative (<https://ocg.cancer.gov/programs/target>), and genomically profiled at the St. Jude Children's Research Hospital or at the Baylor College of Medicine using Gene Chip Human Mapping 500 K Array (Affymetrix) or SeqCap EZ Human Exome 2.0 (Nimblegen), respectively (Table S3). Data used for the analysis is available at <https://portal.gdc.cancer.gov/projects>. Patients diagnosed with B-ALL at age <18 and having reported EFS values were included, while exclusion criteria comprised Down-syndrome and early toxicity during induction therapy. After reviewing the Affymetrix 500 K Array results downloaded from the TARGET website, CNAs with copy number

segments of >2.3 or <0.7 as reported by the St. Jude Children's Research Hospital were considered in our validation analyses. Whole-exome sequencing derived BAM files aligned to the reference genome Human Build 37 (NCBI) were downloaded and CNAs were called by the CNVkit v.0.9.10.dev0 utilizing a circular binary segmentation method [34–36]. Log2 ratio estimates were normalized based on sex of the patients and on reported leukemic cell purity assessed by flow cytometry. Genetic subgroups and 5-year EFS in the validation cohort and in our in-house discovery cohort are shown in Table S4 and Fig. S2.

Statistical analysis

Co-segregation of disease-relevant CNAs were analyzed using the “somaticInteraction” function of maftools Bioconductor package (v2.2.10) which performed pairwise Fisher's exact tests and identified significant mutually exclusive or co-occurring events [37]. Event-free survival (EFS) up to 5 years was defined as the time from start of treatment to relapse, second malignancy or disease-related death, excluding early toxicity. Mean follow-up time was 46.6 months (range: 1.5–72.0 months) with at least 24.0 months at patients experiencing no event during the study period. Cox regression models were used for assessing the association of individual genetic aberrations with risk of progression and for building models for progression prediction. Survival rates were estimated using the Kaplan-Meier method and compared by log-rank tests coupled with Benjamini-Hochberg false discovery rate correction. Statistical analyses were performed using R version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria, 2021).

RESULTS

Frequency and distribution of chromosomal and subchromosomal copy number aberrations

In total, 1398 CNAs including gross chromosomal alterations and subchromosomal lesions were detected in 244/260 (93.8%) diagnostic patient samples. On average, 5.4 CNAs were observed per patient with a mean of 2.5 subchromosomal aberrations. Ninety percent of whole chromosome changes were observed in patients bearing hyperdiploid karyotype with 4–14 affected chromosomes, predominantly extra copies of chromosomes 21, 6, X, 14, 18, 17, 4 and 10 (Fig. S3). Gain of multiple copies was recurrently observed at chromosomes 21, X, 14 and 18. Modal chromosome number among the 82 patients harboring high-hyperdiploid karyotype ranged between 51 and 62 with a median of 55, while one patient displayed near-triploidy with 72 chromosomes.

Subchromosomal CNAs were identified in 208/260 (80.0%) patients with *VPREB1* deletion being the most common lesion occurring in 32.3% of the cases. Additional genes altered with a frequency of at least 5% in our patient cohort included various cell cycle control, lymphoid development, signaling or tumor suppressor genes such as *CDKN2A/B*, *ETV6*, *PAX5*, *IKZF1*, *MLLT3*, *TBL1XR1*, *BTG1*, *RB1*, *BTLA/CD200*, *CASP8AP2*, *RUNX1* as well as the *PAR1* region (Table 1). Seventy percent of biallelic losses included the *VPREB1* and *CDKN2A/B* genes while over two-thirds of the

Table 1. Targets of subchromosomal copy number aberrations detected in diagnostic samples of our 260 patients and ranked in order of frequency.

Lesion	Gene	Total number of aberrations	Biallelic losses / multiple gains	Subclonal alterations
Loss	<i>VPREB1</i>	84	18	5
	<i>CDKN2A/B</i>	72	28	5
	<i>ETV6</i>	68	4	6
	<i>PAX5</i>	43	0	6
	<i>IKZF1</i>	34	1	5
	<i>MLLT3</i>	28	5	4
	<i>PAR1</i>	20	0	2
	<i>TBL1XR1</i>	19	1	0
	<i>BTG1</i>	17	0	0
	<i>RB1</i>	15	6	0
	<i>BTLA/CD200</i>	15	0	0
	<i>CASP8AP2</i>	15	0	2
	<i>TP53</i>	10	1	1
	<i>CTCF</i>	9	0	1
	<i>NR3C1</i>	8	0	2
	<i>EBF1</i>	5	0	0
	<i>ERG</i>	4	0	0
	<i>LEF1</i>	4	0	0
	<i>PTEN</i>	4	0	2
	<i>NF1</i>	3	0	0
	<i>NR3C2</i>	3	0	0
	<i>EZH2</i>	2	0	0
	<i>SUZ12</i>	2	0	0
	<i>IKZF2</i>	1	1	0
	<i>NOTCH1</i>	1	0	0
	<i>PHF6</i>	1	0	0
<i>PTPN2</i>	1	0	0	
Gain	<i>RUNX1</i>	23	11	1
	<i>PHF6</i>	11	4	0
	<i>ABL1</i>	6	1	0
	<i>MYB</i>	1	0	0

multiple gains affected *RUNX1*. Approximately 8% of the subchromosomal CNAs were detected as subclonal aberrations which encompassed the *ETV6*, *PAX5*, *CDKN2A/B*, *IKZF1* and *VPREB1* genes in majority of the cases. Dosage quotient values indicating the fusion and amplification of the *NUP214* and *ABL1* genes were observed in two patients. Considering the genetic subtypes of pediatric B-ALL, the highest average numbers of subchromosomal aberrations (4.8–5.0 CNAs per patient) were observed in the *BCR-ABL1*-positive and *iAMP21* subgroups, while the lowest values with 1.2–1.7 CNAs per patient were associated with hyperdiploidy and *TCF3-PBX1* fusion (Table S5).

Simultaneous presence of various CNAs and B-ALL subgroup defining alterations was investigated in order to reveal potential

associations between individual genetic lesions (Fig. 1). The vast majority of mutual exclusivity or negative correlations was observed in the high-hyperdiploid subgroup, while the pairwise analyses revealed 35 significant positive correlations across various disease subtypes. The strongest positive associations were observed in the *ETV6-RUNX1* subgroup and included *ETV6* loss, *RUNX1* gain and *VPREB1* loss. Among patients with *iAMP21*, enrichment of *CDKN2A/B* loss and *RB1* deletion was observed. *IKZF1*, *MLLT3* and *CD200/BTLA* losses were associated with *BCR-ABL1* positivity, while *IKZF1* loss showed negative correlation with *ETV6-RUNX1* fusion and hyperdiploidy. Beyond that, *IKZF1* deletion showed significant co-occurrence with *TP53*, *BTG1* and *MLLT3* as well as with deletion of the *PAR1* region.




Fig. 1 Co-segregation analysis of genetic subgroup defining alterations and copy number aberrations affecting genes recurrently altered in pediatric B-ALL. Co-occurrence and mutual exclusivity between various B-ALL subgroup defining alterations and/or detected copy number aberrations are labeled with green and brown colors, respectively. Significant ($p < 0.05$) associations revealed by pair-wise Fisher's exact test are marked with asterisks.




Fig. 2 Event-free survival of high-hyperdiploid patients with presence or absence of double trisomy affecting chromosomes 4 and 6. High-hyperdiploid patients with extra chromosomes of 4 and 6 showed higher estimated 5-year EFS rate than other high-hyperdiploid patients in our cohort (93.2% vs. 60.4%).

Hyperdiploidy and prognosis

Whole chromosome gains were investigated individually and in combinations to identify specific patterns associated with favorable outcome among patients with high-hyperdiploid karyotype as revealed or confirmed by digitalMLPA. Simultaneous survival rate analyses using the Kaplan-Meier method unraveled multiple single, double and triple trisomies as markers of good risk, mainly including various combinations of chromosomes 4, 6, 10, 17 and 18, and excluding gains of chromosomes 5 and 20. Due to multiple statistical comparisons of these combinations, results were corrected using the Bonferroni method, after which double trisomy of chromosomes 4 and 6 remained as the only marker significantly associated with superior outcome within the high-hyperdiploid subgroup (Fig. 2).

IKZF1 status and its prognostic value

The D007 probemix covers all exons of the *IKZF1* gene with two probes, as well as regions located approximately 4 and 2 kilobases upstream of the coding sequences, enabling a fine mapping of deletions affecting the *IKZF1* gene. In patients harboring *IKZF1* loss, 10 different patterns of deletion were observed, predominantly exons 4–7 and exons 1–7 losses, as well as deletion of the whole gene including the upstream region (Fig. S4). Notably, we observed a non-random distribution of *IKZF1*^{del} and *IKZF1*^{plus} statuses across patients displaying different patterns of *IKZF1* deletion. Eight out of nine patients with exons 4–7 loss and 6/7 patients with upstream region/exons 1–8 (i.e. whole *IKZF1*) deletion showed *IKZF1*^{plus} CNA profile. On the other hand, all patients with exon 1–7 deletion belonged to the *IKZF1*^{del} group, without meeting the criteria of *IKZF1*^{plus}. By analyzing the prognostic value of *IKZF1* status in our patient cohort, a decreasing rate of EFS was observed in patients with normal vs *IKZF1*^{del} vs *IKZF1*^{plus} genotype; however, the difference between the latter two categories did not reach statistical significance (Fig. S5). We hypothesized that co-evaluation of *IKZF1* status and additional cytogenetic features interdependently may improve the *IKZF1*-driven prognostic risk assessment. In order to generate these

novel subgroups, we combined the *IKZF1* status with cytogenetic categories defined and applied successfully in previous studies (Fig. S6) [16, 30, 31], which eventually allowed for distinguishing three prognostic groups (IKAROS-low, IKAROS-medium and IKAROS-high) with significantly different 5-year EFS (Fig. 3).

Integrative genetic classification for personalized risk assessment

In order to establish a highly personalized risk assessment of patients with B-cell precursor ALL, we introduced a novel classification called PersonALL, which flexibly takes account of the unique composition of aberrations in individual patients. First, prognostic significance of all disease-relevant, recurrent genetic aberrations detected by digitalMLPA or by conventional approaches such as karyotyping and FISH was evaluated in our patient cohort using univariate Cox proportional hazard models. Second, aberrations with a frequency of >1.5% and a Cox model hazard ratio of >1.5 or ≤0.66 were selected and used for calculating patient-specific cumulative scores. The scoring system proportionally weighted individual cytogenetic aberrations and subchromosomal CNAs as outlined in Table S6. Patient-specific cumulative scores generated from the prognostic value of single genetic lesions distinguished four prognostic subgroups with excellent (score: ≥4), good (score: 0–3), high (score: –1 to –4) and ultra-poor risk (score: ≤ –4), demonstrating significantly different 5-year EFS rates (Fig. 4). The excellent, good, high and ultra-poor risk groups comprised 40.4%, 20.0%, 28.5% and 11.1% of the patients, respectively. The excellent risk group almost exclusively contained patients with *ETV6/RUNX1* fusion or high-hyperdiploid karyotype with common double trisomy of chromosomes 4 and 6. An increased fraction of B-other cases coupled with reduced representativity of *ETV6/RUNX1* positivity and high-hyperdiploidy was observed in the good risk group. In the high-risk group, almost two-thirds of the patients were classified as B-other, while the ultra-poor risk group was enriched for *BCR/ABL1* gene fusion, other gene fusions including *CRLF2* and *ABL* class aberrations characteristic of Ph-like signature and *iAMP21* genotype (Fig. 5).




Fig. 3 Event-free survival of 260 patients classified by combined cytogenetic and *IKZF1* copy number status. Risk groups were determined as outlined in Fig. S6. Patients in the IKAROS-low, IKAROS-medium and IKAROS-high groups showed an estimated 5-year EFS rate of 86.3%, 57.4% and 37.5%, respectively.

Performance of PersonALL was validated on an independent cohort of 606 patients included in the TARGET ALL Phase 1 Pilot and Phase 2 Expansion studies, using a scoring scheme identical to the one applied at our in-house discovery cohort. Comparison of the excellent, good, high and ultra-poor risk groups consisting of 30.0%, 24.1%, 39.6% and 6.3% of the patients, respectively, demonstrated significantly different 5-year EFS rates (Fig. 6a). In addition, we tested this novel risk assessment method on the merged dataset comprising relevant information from all patients ($n = 866$) included in the validation cohort and in our discovery cohort. The difference in 5-year EFS across the risk groups showed even higher statistical significance than observed in the validation cohort, thus providing further confirmation on the value and robustness of our newly introduced prognostic classifier (Fig. 6b).

DISCUSSION

Risk assessment based on molecular features of leukemic blasts is gaining increased importance in the clinical stratification of children with B-ALL. Several recurrent CNAs including whole chromosome aberrations and focal alterations have prognostic and/or predictive significance which has led to the incorporation of CNAs into various risk classifiers [16, 26, 29–31]. While co-segregation of different driver aberrations was reported in large-scale genomic studies, flexible prognostic classification approaches adaptively considering the specific combination of genetic lesions in individual patients have not been established to date.

In this study, we used digitalMLPA, a robust high-throughput method for screening disease-relevant CNAs in a nation-wide cohort of Hungarian children diagnosed with B-ALL. While the general feasibility of our approach had previously been demonstrated [16], the significantly larger patient population in the current analysis allowed us to go beyond a simple validation of observations made before. Detection of chromosomal and large subchromosomal CNAs along with exon-level mapping of focal driver aberrations provided prognostically relevant results by (i)

unveiling chromosomal gains associated with the most favorable EFS in the high-hyperdiploid subgroup, (ii) identifying *IKZF1* deletion patterns specifically associated with *IKZF1*^{del} and *IKZF1*^{plus} genotypes, (iii) facilitating the establishment of a cytogenetically aware patient classification based on IKAROS status, and most importantly, (iv) allowing us to design and successfully test a conceptually novel prognostic classifier called PersonALL which dynamically takes into account all possible combinations of potentially co-segregating genetic aberrations screened by digitalMLPA and/or more conventional methods.

Molecular and cytogenetic characterization of the diagnostic samples provided evidence of representativity of our patient cohort in terms of genetic subgroups, frequency of chromosomal and subchromosomal driver aberrations, as well as co-segregation of key recurrent alterations. For example, we observed enrichment of *IKZF1* deletions in the *BCR-ABL1* positive subgroup, common *ETV6* and *TBL1XR1* losses in patients harboring *ETV6-RUNX1* fusion, co-occurrence of *IKZF1* losses with deletions in the *PAR1* and 9p regions or in the *BTG1* gene, and frequent emergence of *RB1* deletion among patients with *iAMP21* genotype [29, 38–43]. The extended number of patients and the digital karyotyping probe subset of the D007 digitalMLPA probemix allowed us to identify specific chromosomal gains associated with superior outcome among patients with high-hyperdiploid karyotype, efficiently supporting the robust implementation of our personalized genetic classifier.

Deletion of the *IKZF1* gene encoding the transcription factor IKAROS is observed in 15–20% of children with B-ALL and it is reported to be associated with inferior clinical outcome with a range of different treatment protocols [27, 44–47]. Stanulla et al. also defined *IKZF1*^{plus}, a very poor, measurable residual disease (MRD)-dependent prognostic subgroup consisting of patients who in addition to *IKZF1* loss, harbor *PAX5*, *CDKN2A/B* or *PAR1* deletion, without concurrent *ERG* loss [29]. Distribution of *IKZF1* deletion patterns in our study resembles previously published data [44], with exon 4–7 deletion (isoform 6 - loss of DNA binding region)




Fig. 4 Event-free survival of 260 patients with B-cell precursor ALL, classified according to patient-specific composition of all disease-relevant aberrations associated with prognostic significance in our patient cohort. Excellent, good, high and ultra-poor risk groups showed an estimated 5-year EFS rate of 96.3%, 87.2%, 67.4% and 39.0%, respectively. Patient-specific scores were calculated as outlined in Table S6.

[48] being the most common subtype, followed by deletions affecting all exons with or without the analyzed upstream region. Various types of *IKZF1* loss confer inferior event-free survival regardless of their frequency and extension albeit at quite different levels of significance when compared with matching wild-type controls [49]. Although the number of patients with *IKZF1* loss was limited in our study, we observed a strong association of specific deletion patterns with either *IKZF1*^{del} or *IKZF1*^{plus} genotype. Importantly, almost all patients harboring exon 4–7 deletion showed *IKZF1*^{plus} genotype which can provide a plausible explanation why this lesion is typically associated with very adverse clinical outcome, even if patients with *IKZF1* loss are exclusively analyzed [49]. This observation certainly needs validation in larger patient cohorts prospectively or retrospectively. In terms of prognosis, our patients displaying *IKZF1* loss with or without fulfilling the criteria of *IKZF1*^{plus} showed significantly shorter EFS compared to patients without *IKZF1* deletion, nevertheless the difference between the two *IKZF1* altered subgroups were not significant, similar to a recent observation by Felice et al. [50]. Therefore, we integrated *IKZF1* status (*IKZF1*^{normal}, *IKZF1*^{del} and *IKZF1*^{plus}) as revealed by digitalMLPA with cytogenetic classes, thus creating a cytogenetics aware interpretation of *IKZF1* allelic status which substantially improved the risk assessment for our patients by distinguishing three prognostic groups with significantly different 5-year EFS.

Pediatric ALL develops via multi-step acquisition of molecular and cytogenetic aberrations, and a subset of alterations shows enriched co-segregation or mutual exclusivity as it has also been demonstrated in our study (Fig. 1). Nevertheless, the specific composition of detectable driver aberrations vary substantially between individual patients which is only considered to a limited extent even by the most recent prognostic classifiers [16, 26, 29, 31]. Therefore, we explored the feasibility of an alternative risk assessment approach which adaptively, at

individual patient level takes into account all aberrations screened and found to be prognostically relevant in our patient cohort. This integrative method that has also been validated on a large independent patient cohort, provides important guidance not only in cases where favorable and adverse prognostic markers are simultaneously present, represented by 25% of our patients, but also allows for a more weighted prognostic classification of each individual patient and hence a refined risk assessment in general. Of note, the conventional classification applied in the ALL IC-BFM protocols failed to define three risk groups with significantly different 5-year EFS rates in our patient cohort (Fig. S7), while four distinct subgroups could be determined using PersonALL, clearly demonstrating the added value of our conceptually novel classifier. The relationships between risk groups defined by the ALL IC-BFM protocols and by the PersonALL method are outlined in Fig. S8. Excellent, good and high-risk groups of the PersonALL classification included patients from all three ALL IC-BFM risk groups and the ultra-poor risk group also involved patients originally classified in different ALL IC-BFM groups, evidently reflecting the more comprehensive principles applied in our new classifier.

Distinguishing four subgroups based on personal composition of genomic lesions as described above may have a direct impact on the clinical management of children with B-ALL in the future. Sixty percent of patients were classified into two prognostically favorable risk groups with a 5-year EFS above 85%, while the other 40% of patients were divided over two risk groups with inferior outcomes (5-year EFS below 70%). Considering the EFS rates of approximately 80–90% in pediatric ALL in the developed countries [51], we may draw some strategic conclusions with regard to the anti-leukemia treatment in these four prognostic subgroups. Reduced therapeutical intensity or longer intervals between consecutive treatment blocks may be considered for patients with “excellent” prognosis to avoid short- and long-term toxicities.




Fig. 5 Distribution of cytogenetic subtypes across four risk groups determined based on non-overlapping ranges of patient specific cumulative scores generated from the prognostic value of single genetic lesions. **a** The excellent risk group almost exclusively comprised patients with *ETV6/RUNX1* gene fusion or high-hyperdiploid (HHD) karyotype. **b, c** The good and the high-risk groups were dominated by patients who classified as B-other in the current study. **d** Two-thirds of the patients in the ultra-poor risk group carried *BCR/ABL1* fusion or alterations characteristic of the Ph-like subtype, with an additional one-fifth of the children in this group harboring *KMT2A* rearrangement or *iAMP21* genotype.




Fig. 6 Validation of PersonALL, a novel classification approach assigning patients to four prognostic subgroups based on highly individualized cumulative scores reflecting the weighted impact of all detected and prognostically relevant genetic aberrations. **a** Event-free survival of 606 patients with B-cell precursor ALL included in the TARGET ALL Phase 1 Pilot or Phase 2 Expansion studies. Excellent, good, high and ultra-poor risk groups showed an estimated 5-year EFS rate of 93.8%, 87.2%, 70.4% and 52.5%, respectively. **b** Event-free survival of 866 (260 + 606) patients with B-cell precursor ALL included in the merged discovery (in-house) and validation cohort. Excellent, good, high and ultra-poor risk groups showed an estimated 5-year EFS rate of 94.7%, 87.2%, 69.8% and 46.8%, respectively.

MRD monitoring and MRD-driven therapy optimization should be a main focus at patients classified in the “good” and, particularly, in the “high-risk” groups. A high-resolution MRD follow-up with patient-specific molecular marker screening and monitoring would be warranted in the “high-risk” group, especially in those countries where the main MRD assessment method is flow cytometry. In cases with “ultra-poor” risk profile, treatment intensification or change in therapeutic approach (e.g. immunotherapy, cell therapy or molecularly targeted therapy) could potentially be initiated even if the early MRD response is promising, due to a very high risk of relapse during and after the first-line ALL treatment.

The current study has some limitations partially coming from the unavailability of MRD data at a significant number of patients which prevented the evaluation of an MRD-guided classifier in this retrospective analysis. Of note, our integrative genetic scoring guide aiding the classification of patients into distinct prognostic groups could still successfully be established even without accounting for the MRD status. Another shortcoming is the low abundance of some typically uncommon but prognostically relevant alterations (e.g. *TCF3-PBX1* and *NUP214-ABL1* fusions) which hampered the incorporation of those into the newly developed classifier. Nevertheless, we do believe our study provides a novel and innovative risk assessment method for patients with pediatric B-ALL, and the proposed approach, also validated on a second patient cohort, can be further refined using prospectively collected large patient populations which on one hand will overcome the limitations mentioned above, on the other hand will allow for additional independent validation of our patient-specific prognostic classifier.

In summary, our study demonstrates the power of comprehensive genomic characterization performed in a highly rationalized manner using digitalMLPA in combination with more conventional cytogenetic and molecular genetic methods. Based on the results, integration of *IKZF1* status with cytogenetic data can facilitate an enhanced IKAROS based prognostic classification which is especially well suited to the diagnostic workflow of laboratories where conventional MLPA is applied in combination with other routine assays. If NGS-based digitalMLPA or other advanced methods are available for the genome-wide characterization of disease-relevant driver aberrations, patient-specific interpretation of results is increasingly warranted and can be achieved by our conceptually novel PersonALL prognostic classifier, that can pave the way for an improved and more refined risk assessment, eventually supporting the highly personalized clinical stratification of children diagnosed with B-ALL.

DATA AVAILABILITY

The materials used and analyzed during the current study are available from the corresponding author on reasonable request.

REFERENCES

- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72:7–33. <https://pubmed.ncbi.nlm.nih.gov/35020204/>
- Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, WHO Classification of Tumours, Revised 4th Edition, 2017 Volume 2 [Internet]. International Agency for Research on Cancer. [cited 2022 Jan 7]. p. 199–208. Available from: <https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017>
- Greaves M Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture. *Hematol Am Soc Hematol Educ Progr.* 2009;3–12. Available from: <https://pubmed.ncbi.nlm.nih.gov/20008176/>
- Bateman CM, Alpar D, Ford AM, Colman SM, Wren D, Morgan M, et al. Evolutionary trajectories of hyperdiploid ALL in monozygotic twins. *Leukemia.* 2015;29:58–65. <https://pubmed.ncbi.nlm.nih.gov/24897505/>

- Ma Y, Dobbins SE, Sherborne AL, Chubb D, Galbiati M, Cazzaniga G, et al. Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia. *Proc Natl Acad Sci USA.* 2013;110:7429–33. <https://pubmed.ncbi.nlm.nih.gov/23569245/>
- Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature.* 2007;446:758–64. <https://pubmed.ncbi.nlm.nih.gov/17344859/>
- Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. *Science.* 2008;322:1377–80. <https://pubmed.ncbi.nlm.nih.gov/19039135/>
- Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. *J Clin Oncol.* 2017;35:975–83. <https://pubmed.ncbi.nlm.nih.gov/28297628/>
- Forero-Castro M, Robledo C, Benito R, Abáigar M, Martín AA, Arefi M, et al. Genome-Wide DNA copy number analysis of acute lymphoblastic leukemia identifies new genetic markers associated with clinical outcome. *PLoS One.* 2016;11. Available from: <https://pubmed.ncbi.nlm.nih.gov/26872047/>
- Paulsson K, Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. *Genes Chromosom Cancer.* 2009;48:637–60. <https://pubmed.ncbi.nlm.nih.gov/19415723/>
- Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. *Nat Genet.* 2015;47:672–6. <https://pubmed.ncbi.nlm.nih.gov/25961940/>
- Pajor L, Szuhaí K, Mehes G, Kosztolányi G, Jáksó P, Lendvai G, et al. Combined metaphase, interphase cytogenetic, and flow cytometric analysis of DNA content of pediatric acute lymphoblastic leukemia. *Cytometry.* 1998;34:87–94. <https://pubmed.ncbi.nlm.nih.gov/9579606/>
- Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigitop H, Schouten JP, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. *Genes Chromosom Cancer.* 2010;49:1104–13. <https://pubmed.ncbi.nlm.nih.gov/20815030/>
- Alpár D, de Jong D, Savola S, Yigitop HA, Kajtár B, Kereskai L, et al. MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia. *Cancer Genet.* 2012;205:465–9. <https://pubmed.ncbi.nlm.nih.gov/22939399/>
- Benard-Slagter A, Zondervan I, de Groot K, Ghazavi F, Sarhadi V, Van Vlierberghe P, et al. Digital multiplex ligation-dependent probe amplification for detection of key copy number alterations in T- and B-cell lymphoblastic leukemia. *J Mol Diagn.* 2017;19:659–72. <https://pubmed.ncbi.nlm.nih.gov/28736295/>
- Kiss R, Gángó A, Benard-Slagter A, Egyed B, Haltrich I, Hegyi L, et al. Comprehensive profiling of disease-relevant copy number aberrations for advanced clinical diagnostics of pediatric acute lymphoblastic leukemia. *Mod Pathol.* 2020;33:812–24. <https://pubmed.ncbi.nlm.nih.gov/31857684/>
- Thakral D, Kaur G, Gupta R, Benard-Slagter A, Savola S, Kumar I, et al. Rapid identification of key copy number alterations in B- and T-cell acute lymphoblastic leukemia by digital multiplex ligation-dependent probe amplification. *Front Oncol.* 2019;9:871.
- Raimondi SC, Pui CH, Hancock ML, Behm FG, Filatov L, Rivera GK. Heterogeneity of hyperdiploid (51–67) childhood acute lymphoblastic leukemia. *Leukemia.* 1996;10:213–24. <https://pubmed.ncbi.nlm.nih.gov/8637229/>
- Heerema NA, Sather HN, SENSEL MG, Zhang T, Hutchinson RJ, Nachman JB, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). *J Clin Oncol.* 2000;18:1876–87. <https://pubmed.ncbi.nlm.nih.gov/10784628/>
- Moorman AV, Richards SM, Martineau M, Cheung KL, Robinson HM, Jalali GR, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. *Blood.* 2003;102:2756–62. <https://pubmed.ncbi.nlm.nih.gov/12829593/>
- Dastugue N, Suciu S, Plat G, Speleman F, Cavé H, Girard S, et al. Hyperdiploidy with 58–66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. *Blood.* 2013;121:2415–23. <https://pubmed.ncbi.nlm.nih.gov/23321258/>
- Harris RL, Harrison CJ, Martineau M, Taylor KE, Moorman AV. Is trisomy 5 a distinct cytogenetic subgroup in acute lymphoblastic leukemia? *Cancer Genet Cytogenet [Internet]* 2004;148:159–62. <https://pubmed.ncbi.nlm.nih.gov/14734231/>
- Vojcek A, Pajor G, Alpár D, Mátics R, Pótó L, Szuhaí K, et al. Conserved hierarchical gain of chromosome 4 is an independent prognostic factor in high hyperdiploid pediatric acute lymphoblastic leukemia. *Leuk Res.* 2017;52:28–33. <https://pubmed.ncbi.nlm.nih.gov/27870946/>
- Harris MB, Shuster JJ, Carroll A, Look AT, Borowitz MJ, Crist WM, et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a pediatric oncology group study. *Blood.* 1992;79:3316–24.

25. Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. *Leukemia*. 2005;19:734–40. <https://pubmed.ncbi.nlm.nih.gov/15789069/>
26. Enshaei A, Vora A, Harrison CJ, Moppett J, Moorman AV. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials. *Lancet Haematol*. 2021;8:e828–39. <https://pubmed.ncbi.nlm.nih.gov/34715050/>
27. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *N Engl J Med*. 2009;360:470–80.
28. Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA, Devidas M, et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and outcome. *Leukemia*. 2014;28:1015–21. <https://pubmed.ncbi.nlm.nih.gov/24166298/>
29. Stanulla M, Dagdan E, Zaliouva M, Mörücke A, Palmi C, Cazzaniga G, et al. IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia. *J Clin Oncol*. 2018;36:1240–9. <https://pubmed.ncbi.nlm.nih.gov/29498923/>
30. Moorman AV, Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. *Blood*. 2014;124:1434–44. <https://pubmed.ncbi.nlm.nih.gov/24957142/>
31. Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbary G, et al. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. *Blood Adv*. 2019;3:148–57. <https://pubmed.ncbi.nlm.nih.gov/30651283/>
32. Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127:2375–90. <https://pubmed.ncbi.nlm.nih.gov/26980727/>
33. Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. *J Clin Oncol*. 2014;32:174–84. <https://pubmed.ncbi.nlm.nih.gov/24344215/>
34. Talevich E, Shain AH, Botton T, Bastian BC CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. *PLoS Comput Biol*. 2016;12. Available from: <https://pubmed.ncbi.nlm.nih.gov/27100738/>
35. Olshen AB, Bengtsson H, Neuvial P, Spellman PT, Olshen RA, Seshan VE. Parent-specific copy number in paired tumor-normal studies using circular binary segmentation. *Bioinforma*. 2011;27:2038–46. <https://pubmed.ncbi.nlm.nih.gov/21666266/>
36. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. *Bioinforma*. 2007;23:657–63. <https://pubmed.ncbi.nlm.nih.gov/17234643/>
37. Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Della Porta MG, Jädersten M, et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. *Nat Commun*. 2015;6. Available from: <https://pubmed.ncbi.nlm.nih.gov/25574665/>
38. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. *Nature*. 2008;453:110–4. <https://pubmed.ncbi.nlm.nih.gov/18408710/>
39. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. *Nat Genet*. 2014;46:116–25. <https://pubmed.ncbi.nlm.nih.gov/24413735/>
40. Parker H, An Q, Barber K, Case M, Davies T, Konn Z, et al. The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. *Genes Chromosomes Cancer*. 2008;47:1118–25. <https://pubmed.ncbi.nlm.nih.gov/18767146/>
41. Usvasalo A, Ninomiya S, Rätty R, Hollmén J, Saarinen-Pihkala UM, Elonen E, et al. Focal 9p instability in hematologic neoplasias revealed by comparative genomic hybridization and single-nucleotide polymorphism microarray analyses. *Genes Chromosomes Cancer*. 2010;49:309–18. <https://pubmed.ncbi.nlm.nih.gov/20013897/>
42. Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, et al. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. *Haematologica*. 2017;102:541–51.
43. Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, et al. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. *Haematologica*. 2013;98:1081–8. <https://pubmed.ncbi.nlm.nih.gov/23508010/>
44. Stanulla M, Cavé H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? *Blood*. 2020;135:252–60.
45. Ayón-Pérez MF, Pimentel-Gutiérrez HJ, Durán-Avelar MDJ, Vibanco-Pérez N, Pérez-Peraza VM, Pérez-González ÓA, et al. IKZF1 gene deletion in pediatric patients diagnosed with acute lymphoblastic leukemia in Mexico. *Cytogenet Genome Res*. 2019;158:10–6. <https://pubmed.ncbi.nlm.nih.gov/30974435/>
46. Van Der Veer A, Waanders E, Pieters R, Willems ME, Van Reijmersdal SV, Russell LJ, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. *Blood*. 2013;122:2622–9. <https://pubmed.ncbi.nlm.nih.gov/23974192/>
47. Waanders E, Van Der Velden VHJ, Van Der Schoot CE, Van Leeuwen FN, Van Reijmersdal SV, De Haas V, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. *Leukemia*. 2011;25:254–8. <https://pubmed.ncbi.nlm.nih.gov/21102428/>
48. Marke R, Van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. *Haematologica*. 2018;103:565–74. <https://pubmed.ncbi.nlm.nih.gov/29519871/>
49. Boer JM, Van Der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, De Groot-Kruseman HA, et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. *Leukemia*. 2016;30:32–8. <https://pubmed.ncbi.nlm.nih.gov/26202931/>
50. Felice MS, Rubio PL, Digioia J, Barreda Frank M, Martínez CS, Gutter MR, et al. Impact of IKZF1 deletions in the prognosis of childhood acute lymphoblastic leukemia in Argentina. *Cancers (Basel)*. 2022;14:3283 <https://pubmed.ncbi.nlm.nih.gov/35805054/>
51. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. *Haematologica*. 2020;105:2524–39. <https://pubmed.ncbi.nlm.nih.gov/33054110/>

ACKNOWLEDGEMENTS

We are grateful to the patients and their families involved in this study. The digitalMLPA probemix and reagents were kindly provided by MRC Holland and the in-house quality control test of the D007-X5-0220 probemix lot was kindly performed by Bastiaan Boerrieger.

AUTHOR CONTRIBUTIONS

DA and BE conceptualized, DA and CsB coordinated the study. GK, DJE, JM, IH, BK, LP, ÁV, GO, AU, ISz, LGyT, KB, KCs, GyP, RS, PH, ÁK, ZsJ, CsK and GK provided patient samples and clinical/pathological annotations; GB, BE, LK, AB, LLH, SzK performed experiments; GB, BE, LK, ABS, KdG, BB, SzK, ES, AM, SS, CsB and DA performed data analysis; GB, BE and DA wrote the paper. All authors have read and critically reviewed the final version of the manuscript.

FUNDING

The study was funded by the Hungarian National Research, Development and Innovation Office (NKFIH) (FK20_134253, K21_137948 and K22_143021), the EU's Horizon 2020 research and innovation program (No. 739593), the Hungarian Pediatric Oncology Network, the Co-operative Doctoral Program of the Ministry for Innovation and Technology (KDP-2020-1008491), the János Bolyai Research Scholarship program (ID: BO/00125/22) of the Hungarian Academy of Sciences, as well as by the Complementary Research Excellence Program of Semmelweis University (EFOP-3.6.3-VEKOP-16-2017-00009), the Ministry of Innovation and Technology of Hungary from the New National Excellence Program (ÚNKP-22-5-SE-7) and from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA-24 and TKP2021-NVA-15 funding schemes and the ELIXIR Hungary. Open access funding provided by Semmelweis University.

COMPETING INTERESTS

ABS, KdG and SS are employees of the MRC Holland (Amsterdam, NL). The authors reported no further conflicts of interest.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Ethical approval (45563-2/2019/EKU) from the Medical Research Council of Hungary and written informed consent from the patients and/or from the parents or guardians

were obtained for the study, which was conducted in accordance with the Declaration of Helsinki.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41416-023-02309-8>.

Correspondence and requests for materials should be addressed to Donát. Alpár.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023